Back to Screener

Healthcare

RegeneRx Biopharmaceuticals, Inc.(RGRX)

Live Price

Offline

$0.0006

+0.00% today

Window Change

+200.00%

Window

Jul 23, 2025 โ†’ Jun 17, 2026

Market Cap
โ€”
Revenue Growth
0.0%
EPS Growth
-7094.2%
Dividend Yield
0.0%

Coverage: 227 bars ยท Jul 23, 2025 โ†’ Jun 17, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

RegeneRx Biopharmaceuticals, Inc. (RGRX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 200.0% across the available one-year price window (Jul 23, 2025 โ†’ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -7094.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -7094.2%, free cash flow +5.0% with operating margin -1826.4% and ROIC 1654.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RGRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

-1826.4% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2023 was reported on Mar 31, 2023, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at 0.0% and EPS is at -7094.2%, with operating margin around -1826.4%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged +2400.0% over the next 5 trading days and finished higher after 3 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2023
Mar 31, 2023
โ€”+0.0%+2400.0%+0.0%
2022
Dec 31, 2022
โ€”+0.0%+2400.0%+0.0%
2022
Sep 30, 2022
โ€”+0.0%+2400.0%+0.0%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

RGRX

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

RGRX Max Drawdown

-99.88%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for RGRX and SPY.

Calendar-year return history is still loading or unavailable.
RegeneRx Biopharmaceuticals, Inc. logo

Company Overview

RegeneRx Biopharmaceuticals, Inc.

Other OTC

Rockville, MD, US
Visit regenerx.comCall IR301 208 9191

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Leadership
J. J. Finkelstein
IPO Date
Oct 7, 2003
Employees
2
Street Address
15245 Shady Grove Road
Mailing
Rockville, MD, 20850
Region
Rockville, MD, US
Reporting Currency
USD
Investor Line
301 208 9191
Last Updated
May 4, 2026
CIK: 0000707511ISIN: US75886X3061CUSIP: 75886X108
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
0.0
Price/Book
โ€”

Growth

Revenue
0.0%
EPS
-7094.2%
Free Cash Flow
+5.0%

Profitability

Gross Margin
100.0%
Operating Margin
-1826.4%
Net Margin
-2249.8%
ROE
60.9%
ROIC
1654.7%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.55

Earnings Reports

๐Ÿ“… Last reportedMar 31, 2023
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Mar 31, 23
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Dec 31, 22
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Sep 30, 22
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Jun 30, 22
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Mar 31, 22
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Dec 31, 21
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Nov 15, 21
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Aug 6, 21
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Mar 31, 21
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Dec 31, 20
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Nov 13, 20
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Aug 14, 20
-0.00
Est โ€”
โ€”
19.2B
Est 17.0B
+12.9%
โ€”
May 15, 20
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Dec 31, 19
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Nov 14, 19
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”
โ€”
Aug 14, 19
-0.00
Est โ€”
โ€”
19.2B
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks